A new lawsuit against the White House is challenging federal laws on cannabis and its medical application in the US. Last week (February 14) arguments were presented for Washington, et.al v. Sessions, a New York case in which the plaintiffs are seeking an update to the major barrier for the full legalization of the drug.

Despite previous similar hearings held across the country, this particular case is gaining momentum thanks to its collection of plaintiffs. The formal lawsuit was filed last year in the Federal District Court in Manhattan and places the Department of Justice, Attorney General Jeff Sessions and the DEA as the defendants for the case.

Alexis Bortell is a 12-year-old girl dealing with epilepsy using a cannabis treatment and one of the plaintiffs at the center of this case. She argued for her right to travel with medicinal cannabis between states and into ones where the drug remains illegal. Jager Cotte

From the remaining five plaintiffs, they include Marvin Washington, a former football player arguing for his right to conduct cannabis-related business in between states. Jager Cotte, another pediatric cannabis patient. The Cannabis Cultural Association (CCA), a nonprofit focused on aiding marginalized communities in the industry, and Jose Belen an Army veteran using cannabis to treat his PTSD.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Advocates hopeful thanks to sympathetic comment from Judge

According to NORML, an advocacy group seeking to change federal marijuana laws, Judge Alvin K. Hellerstein of the U.S. District Court for the Southern District of New York showed sympathy for the plaintiffs by asking how anyone could say their lives had not “been saved by marijuana.”

However, Hellerstein agreed with the government’s argument that “the plaintiffs have not petitioned the Drug Enforcement Agency to reclassify marijuana,” a report from the Associated Press said last Wednesday.

“The lawsuit claims that the government’s decision to classify marijuana as dangerous is irrational, unconstitutional and motivated by politics,” the report said.

On the government’s side, Justice Department lawyers requested the case to be dismissed based on the current federal stance against marijuana.

“Because such a right is not ‘implicit in the concept of ordered liberty’ or ‘deeply rooted in this Nation’s history,’ the Court should reject such a claim,” NORML wrote.

Cannabis remains illegal under the federal system in the US in accordance with the Controlled Substance Act. The Act catalogs the plant as a Schedule I drug, “the most restrictive category reserved for the most dangerous narcotics,” the New York Times wrote.

CCA co-founder and deputy director Jake Plowden told Cannabis Now this case could represent the actual de-scheduling of cannabis as a Schedule I drug and “ultimately ending global cannabis prohibition.”

This case picked up steam from the decision by Sessions to rescind Obama-era guidance protecting the cannabis industry. The uncertainty of the market was increased last month when Sessions introduced his own memorandum allowing federal prosecutors to use their law against cannabis companies if they deemed it so.

Since the change in policy, there hasn’t been a crackdown on companies operating in the States. However, public companies in Canada had to provide an update on their risk disclosures to potential shareholders.

Investor Takeaway

As this case continues to gain prominence, there could be developments affecting the laws in the US, a country holding some of the biggest markets available.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less